Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2009

View Archived Issues

EMEA accepts for review Schering-Plough's MAA for Sycrest for schizophrenia and bipolar I disorder

Otsuka claims novel collagen production suppressant compounds for cancer treatment

Novel G-protein coupled receptor 40 agonists for the treatment of diabetes discovered by Merck & Co.

Janssen describes adenosine A2A receptor antagonists for the treatment of Parkinson's disease

Nissan Chemical presents P2X7 receptor antagonists for the treatment of rheumatoid arthritis

Dopamine D3 receptor ligands for the treatment of schizophrenia discovered by Abbott

KineMed and Bristol-Myers Squibb sign collaboration agreement in Alzheimer's disease

Meda completes seventh phase III study of azelastine nasal spray for allergic rhinitis

Phase II NT-501 trial demonstrates strong biological effect in retinitis pigmentosa

EMEA grants orphan drug designation for AMT-021 for acute intermittent porphyria

Cytori completes enrollment in PRECISE trial of Celution in chronic myocardial ischemia

Amarillo Biosciences provides update on phase II influenza study in Australia

BioPartners withdraws Biferonex (interferon beta-1a) application from EMEA

Catalyst reports results for phase II CPP-109 trial for cocaine addiction

CSL enters agreements with U.S. and Australian government for swine flu vaccine

FDA approves Besivance for bacterial conjunctivitis

Clinical Data acquires Avalon Pharmaceuticals

AstraZeneca provides regulatory update for Seroquel XR for MDD

Incyte changes primary endpoint for U.S. phase III COMFORT-I trial of INCB-18424

FDA issues complete response letter regarding Johnson & Johnson's NDA for rivaroxaban

Intercell initiates enrollment in phase II clinical trial of VE patch for H5N1 influenza

MediciNova amends dosing regimen for phase II MN-221-CL-007 trial of MN-221 in asthma

Target inhibition seen with Akt inhibitor MK-2206 in solid tumor patients

Phase I data on GDC-0941 in solid tumors reported

Oncolytic virus active in patients with neuroendocrine cancers

TAL-6004 safe and well tolerated in patients with alpha1-antitrypsin deficiency

Recently developed CRTH2 antagonist decreases allergic rhinitis responses in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Heartbeam wins appeal, gains FDA clearance
BioWorld MedTech
Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram...